Company news
CNBX Pharmaceuticals Inc. news in 2021
CNBX Pharmaceuticals Inc.'s news releases, calls and decks from 2021, newest first.
CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials
November 4, 2021
Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago
October 26, 2021
Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors
October 25, 2021
EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX
October 21, 2021
CNBX Director, Dr. Inbar Maymon-Pomeranchik, to Participate at MJBizCon in Las Vegas
October 20, 2021
CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
October 19, 2021
Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
October 18, 2021
CEO Eyal Barad and Dr. David Sans from Cannabics Pharmaceuticals in NYC, to Participate at Benzinga's Cannabis Capital Conference
October 14, 2021
Cannabics Announces New Corporate Logo, New Website and New Company Presentation
September 30, 2021
Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston
September 22, 2021
Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases
September 21, 2021
Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
September 13, 2021
Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors
August 23, 2021
World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors
August 4, 2021
Cannabics Pharmaceuticals Appoints a Second Independent Board Member
July 20, 2021
Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
July 7, 2021
Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice
June 28, 2021
Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases
June 17, 2021
Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program
June 3, 2021
The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology
May 25, 2021
Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations
May 11, 2021
Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI)
May 6, 2021
Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track
April 26, 2021
Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program
April 20, 2021
Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33
March 31, 2021
Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells
March 17, 2021
Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016
February 17, 2021
Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
February 16, 2021
Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
February 3, 2021